trending Market Intelligence /marketintelligence/en/news-insights/trending/czIw4443paVh8Vt_POZpUg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Generex Biotechnology acquires 51% of NY-based wound gel maker Olaregen

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Generex Biotechnology acquires 51% of NY-based wound gel maker Olaregen

Generex Biotechnology Corp. completed its purchase of a 51% stake in Olaregen Therapeutix Inc.

New York-based Olaregen is a regenerative medicine company preparing to launch its wound conforming gel matrix Excellagen, which has received clearance from the U.S. Food and Drug Administration to treat wounds such as diabetic ulcers and surgical wounds.

Under the deal's terms, Generex is paying $400,000 up front and could make an additional $11.6 million in milestone payments.

Generex Biotechnology, which develops cancer therapies, medical devices and diagnostics, recently acquired Regentys Corp., a Miami-based regenerative drug company manufacturing treatments targeting gastrointestinal disorders.